H.C. Wainwright Starts Neuralstem (CUR) at Neutral

H.C. Wainwright initiated coverage on Neuralstem (NYSE: CUR) with a Neutral rating.

Analyst Reni Benjamin said, "We are initiating coverage of Neuralstem Inc. with a Neutral rating without a price target, based on a discounted earnings per share and revenue multiple analysis."

"Neuralstem’s core biotechnology franchise takes advantage of allogeneic fetal neuronal stem cell lines which are being evaluated as cell-based regenerative therapies in neurological indications. The company’s lead product candidate, NSI-566, is a stem cell treatment that recently reported preliminary yet promising results in Amyotrophic Lateral Sclerosis (ALS). Results were also reported for a second drug candidate, NSI-189, from a small Phase 1 study in patients with Major Depressive Disorder (MDD). Although the company has a multipronged portfolio designed to target unmet medical needs and a cash position of $30.2 MM that we expect to last till mid-2016, we believe Neuralstem shares are currently fairly valued," he added.

For an analyst ratings summary and ratings history on Neuralstem click here. For more ratings news on Neuralstem click here.

Shares of Neuralstem closed at $3.78 yesterday.

You May Also Be Interested In

• Jefferies Upgrades Kite Realty Group (KRG) to Buy
• Knight Transportation (KNX) PT Lowered to $54 at BofA Securities
• Netflix's subscribers, TSMC, Tesla upside - what's moving markets